Thrombocythemia, Essential
"Thrombocythemia, Essential" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.
MeSH Number(s)
C15.378.100.832
C15.378.140.860.800
C15.378.190.636.860.800
C15.378.463.825
Concept/Terms
Thrombocythemia, Essential- Thrombocythemia, Essential
- Essential Thrombocythemia
- Essential Thrombocythemias
- Thrombocythemias, Essential
- Thrombocythemia, Primary
- Primary Thrombocythemia
- Primary Thrombocythemias
- Thrombocythemias, Primary
- Thrombocythemia, Idiopathic
- Idiopathic Thrombocythemia
- Idiopathic Thrombocythemias
- Thrombocythemias, Idiopathic
- Hemorrhagic Thrombocythemia
- Thrombocythemia, Hemorrhagic
- Hemorrhagic Thrombocythemias
- Thrombocythemias, Hemorrhagic
Below are MeSH descriptors whose meaning is more general than "Thrombocythemia, Essential".
Below are MeSH descriptors whose meaning is more specific than "Thrombocythemia, Essential".
This graph shows the total number of publications written about "Thrombocythemia, Essential" by people in Harvard Catalyst Profiles by year, and whether "Thrombocythemia, Essential" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 1 | 2 |
| 1994 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2006 | 3 | 0 | 3 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 3 | 0 | 3 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 2 | 4 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 4 | 0 | 4 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 1 | 3 |
Below are the most recent publications written about "Thrombocythemia, Essential" by people in Profiles.
-
Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis. Ann Hematol. 2021 Jan; 100(1):105-116.
-
Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020 11; 98:106459.
-
Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms. Cancer Med. 2020 03; 9(6):2039-2051.
-
Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia. 2020 02; 34(2):510-521.
-
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors. Hematol Oncol. 2019 Aug; 37(3):291-295.
-
Pulmonary Artery Catheter Thrombus in a Patient With Essential Thrombocytosis: A Case Report. A A Pract. 2019 Apr 15; 12(8):292-294.
-
EVALUATION OF BURDENSOME SYMPTOMS IN PATIENTS WITH RADIATION6ASSOCIATED AND SPONTANEOUS MYELOPROILIFERATIVE NEOPLASMS WITH THE USE OF OPTIMIZED SELF-ASSESSMENT MPN-SAF TSS. Probl Radiac Med Radiobiol. 2018 Dec; 23:510-516.
-
Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation. Am J Hematol. 2019 04; 94(4):504-505.
-
The comorbidity of acute ischemic stroke and splenic infarction resulting from essential thrombocythemia. Neurol Sci. 2018 10; 39(10):1787-1790.
-
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. Blood Cancer J. 2018 06 11; 8(6):56.